title: Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend.
abstract: There have been two strategies developed in the recent literature for quantitative control of the targeting effects for drug delivery by ligand-conjugated nanoparticles of biodegradable copolymer blend such as PLGA/PLGA-PEG, i.e. the pre-conjugation strategy and the post-conjugation strategy, in which the ligand conjugation was made before and after the nanoparticle formulation respectively. This research developed another drug delivery system of the PLA-TPGS/TPGS-COOH copolymer blend and further improved the post-conjugation strategy to precisely control the targeting effects by two ways: one is to adjust the PLA-TPGS:TPGS-COOH copolymer blend ratio in the nanoparticle formulation process, which provides a way for coarse control, and another is to control the feeding concentration of the ligand in the herceptin conjugation process, which further provides a fine control. Herceptin conjugation was visualized by the FETEM with immumogold labeling and further quantified by the two techniques, i.e. the Bradford assay and the flow cytometry to confirm each other. The positive correlation between the surface density of the ligand and the cellular internalization as well as the cytotoxicity of the nanoparticle formulations was assessed, which demonstrated that the strategy developed in this research is simple and feasible, which can precisely control the targeting effects of the nanoparticles of biodegradable polymers as well as other nanocarriers such as micelles and liposomes.
authors.affiliation: Department of Bioengineering, National University of Singapore, Singapore 117576, Singapore.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Yu
authors.initials: Y
authors.lastname: Mi
authors.forename: Yutao
authors.initials: Y
authors.lastname: Liu
authors.forename: Si-Shen
authors.initials: SS
authors.lastname: Feng
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000737:chemistry; D001673:Biodegradation, Environmental; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D006801:Humans; D007150:Immunohistochemistry; D019344:Lactic Acid / Q000737:chemistry; D008024:Ligands; D053758:Nanoparticles / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D010316:Particle Size; D011091:Polyesters; D011092:Polyethylene Glycols / Q000737:chemistry; D011108:Polymers / Q000737:chemistry*; D013499:Surface Properties; D000068878:Trastuzumab; D014810:Vitamin E / Q000031:analogs & derivatives / Q000737:chemistry
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D008024:Ligands; D011091:Polyesters; D011108:Polymers; D014810:Vitamin E; D019344:Lactic Acid; D011092:Polyethylene Glycols; C033616:poly(lactide); C014225:tocophersolan; D000068878:Trastuzumab